Miriam Monge to Join Sartorius Stedim Biotech
News Aug 27, 2014
Sartorius Stedim Biotech (SSB) has announced the appointment of Miriam Monge as Director of Marketing for SSB’s Integrated Solutions unit. In this newly created position, Monge will focus on sharpening SSB’s profile as an integrated solution provider for the biopharmaceutical industry.
Miriam Monge brings in more than 20 years of experience in the biopharmaceutical manufacturing sector and served, most recently, as Vice President of Sales & Marketing at the consultancy Biopharm Services.
She is a committee member of the International Society for Pharmaceutical Engineering (ISPE) and one of the founders of the Global Disposable Community of Practice. Miriam Monge regularly authors articles for technical bioprocess journals, analyzing the impact of disposable technologies on biomanufacturing.
“With Miriam Monge, we have gained an internationally recognized expert from the biopharmaceutical industry who will help us further position Sartorius Stedim Biotech as a total solution provider for biopharma companies,” stated Reinhard Vogt, member of the SSB Board of Directors.
Vogt continued, “Whenever our customers start planning a new facility or process, SSB’s Integrated Solutions unit is an ideal partner for designing and implementing entire single-use or hybrid production processes.”
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018